Patterns and predictors of Warfarin use in patients with new-onset atrial fibrillation from the FRACTAL registry

Matthew R. Reynolds, Jignesh Shah, Vidal Essebag, Brian Olshansky, Paul Andrew Friedman, Tomy Hadjis, Robert Lemery, Tristram D. Bahnson, David S. Cannom, Mark E. Josephson, Peter Zimetbaum

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Warfarin is underused for stroke prevention in atrial fibrillation (AF). Previous studies addressing this have lacked longitudinal assessment. This study sought to characterize contemporary warfarin use in new-onset AF and evaluate its change over time. It was hypothesized that AF recurrence has an important influence on warfarin use patterns. One thousand five adults from 17 centers in the United States and Canada were enrolled into a prospective observational registry after their first documented episodes of AF. Detailed demographic, clinical history, and management data were collected on all subjects at enrollment, including medication use. Patients were followed at regular intervals for interim events and changes in AF management. Warfarin use at baseline and last follow-up (mean 25 ± 8 months) after enrollment was modeled using multivariate analysis. Initially, 65% of subjects were prescribed warfarin, but only 44% were taking it at 30 months. Even in "ideal" candidates for warfarin, the rate of warfarin prescription decreased from 70% at baseline to 50% at 30 months. Stroke risk factors, including hypertension, congestive heart failure, valvular heart disease, and previous stroke or transient ischemic attack were significant predictors of warfarin prescription at baseline. At last follow-up, the relation between AF recurrence and warfarin use (odds ratio 2.3, 95% confidence interval 1.6 to 3.1) was stronger than that for any individual stroke risk factor. In conclusion, predictors of warfarin use in patients with AF include AF recurrence and selected stroke risk factors. The discontinuation of warfarin in a large number of patients with AF over time is a cause for concern in light of data from recent clinical trials.

Original languageEnglish (US)
Pages (from-to)538-543
Number of pages6
JournalAmerican Journal of Cardiology
Volume97
Issue number4
DOIs
StatePublished - Feb 15 2006

Fingerprint

Warfarin
Atrial Fibrillation
Registries
Stroke
Recurrence
Prescriptions
Heart Valve Diseases
Transient Ischemic Attack
Canada
Multivariate Analysis
Heart Failure
Odds Ratio
Demography
Clinical Trials
Confidence Intervals
Hypertension

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Patterns and predictors of Warfarin use in patients with new-onset atrial fibrillation from the FRACTAL registry. / Reynolds, Matthew R.; Shah, Jignesh; Essebag, Vidal; Olshansky, Brian; Friedman, Paul Andrew; Hadjis, Tomy; Lemery, Robert; Bahnson, Tristram D.; Cannom, David S.; Josephson, Mark E.; Zimetbaum, Peter.

In: American Journal of Cardiology, Vol. 97, No. 4, 15.02.2006, p. 538-543.

Research output: Contribution to journalArticle

Reynolds, MR, Shah, J, Essebag, V, Olshansky, B, Friedman, PA, Hadjis, T, Lemery, R, Bahnson, TD, Cannom, DS, Josephson, ME & Zimetbaum, P 2006, 'Patterns and predictors of Warfarin use in patients with new-onset atrial fibrillation from the FRACTAL registry', American Journal of Cardiology, vol. 97, no. 4, pp. 538-543. https://doi.org/10.1016/j.amjcard.2005.09.086
Reynolds, Matthew R. ; Shah, Jignesh ; Essebag, Vidal ; Olshansky, Brian ; Friedman, Paul Andrew ; Hadjis, Tomy ; Lemery, Robert ; Bahnson, Tristram D. ; Cannom, David S. ; Josephson, Mark E. ; Zimetbaum, Peter. / Patterns and predictors of Warfarin use in patients with new-onset atrial fibrillation from the FRACTAL registry. In: American Journal of Cardiology. 2006 ; Vol. 97, No. 4. pp. 538-543.
@article{c80255a63d314a128afe53976af3fea5,
title = "Patterns and predictors of Warfarin use in patients with new-onset atrial fibrillation from the FRACTAL registry",
abstract = "Warfarin is underused for stroke prevention in atrial fibrillation (AF). Previous studies addressing this have lacked longitudinal assessment. This study sought to characterize contemporary warfarin use in new-onset AF and evaluate its change over time. It was hypothesized that AF recurrence has an important influence on warfarin use patterns. One thousand five adults from 17 centers in the United States and Canada were enrolled into a prospective observational registry after their first documented episodes of AF. Detailed demographic, clinical history, and management data were collected on all subjects at enrollment, including medication use. Patients were followed at regular intervals for interim events and changes in AF management. Warfarin use at baseline and last follow-up (mean 25 ± 8 months) after enrollment was modeled using multivariate analysis. Initially, 65{\%} of subjects were prescribed warfarin, but only 44{\%} were taking it at 30 months. Even in {"}ideal{"} candidates for warfarin, the rate of warfarin prescription decreased from 70{\%} at baseline to 50{\%} at 30 months. Stroke risk factors, including hypertension, congestive heart failure, valvular heart disease, and previous stroke or transient ischemic attack were significant predictors of warfarin prescription at baseline. At last follow-up, the relation between AF recurrence and warfarin use (odds ratio 2.3, 95{\%} confidence interval 1.6 to 3.1) was stronger than that for any individual stroke risk factor. In conclusion, predictors of warfarin use in patients with AF include AF recurrence and selected stroke risk factors. The discontinuation of warfarin in a large number of patients with AF over time is a cause for concern in light of data from recent clinical trials.",
author = "Reynolds, {Matthew R.} and Jignesh Shah and Vidal Essebag and Brian Olshansky and Friedman, {Paul Andrew} and Tomy Hadjis and Robert Lemery and Bahnson, {Tristram D.} and Cannom, {David S.} and Josephson, {Mark E.} and Peter Zimetbaum",
year = "2006",
month = "2",
day = "15",
doi = "10.1016/j.amjcard.2005.09.086",
language = "English (US)",
volume = "97",
pages = "538--543",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Patterns and predictors of Warfarin use in patients with new-onset atrial fibrillation from the FRACTAL registry

AU - Reynolds, Matthew R.

AU - Shah, Jignesh

AU - Essebag, Vidal

AU - Olshansky, Brian

AU - Friedman, Paul Andrew

AU - Hadjis, Tomy

AU - Lemery, Robert

AU - Bahnson, Tristram D.

AU - Cannom, David S.

AU - Josephson, Mark E.

AU - Zimetbaum, Peter

PY - 2006/2/15

Y1 - 2006/2/15

N2 - Warfarin is underused for stroke prevention in atrial fibrillation (AF). Previous studies addressing this have lacked longitudinal assessment. This study sought to characterize contemporary warfarin use in new-onset AF and evaluate its change over time. It was hypothesized that AF recurrence has an important influence on warfarin use patterns. One thousand five adults from 17 centers in the United States and Canada were enrolled into a prospective observational registry after their first documented episodes of AF. Detailed demographic, clinical history, and management data were collected on all subjects at enrollment, including medication use. Patients were followed at regular intervals for interim events and changes in AF management. Warfarin use at baseline and last follow-up (mean 25 ± 8 months) after enrollment was modeled using multivariate analysis. Initially, 65% of subjects were prescribed warfarin, but only 44% were taking it at 30 months. Even in "ideal" candidates for warfarin, the rate of warfarin prescription decreased from 70% at baseline to 50% at 30 months. Stroke risk factors, including hypertension, congestive heart failure, valvular heart disease, and previous stroke or transient ischemic attack were significant predictors of warfarin prescription at baseline. At last follow-up, the relation between AF recurrence and warfarin use (odds ratio 2.3, 95% confidence interval 1.6 to 3.1) was stronger than that for any individual stroke risk factor. In conclusion, predictors of warfarin use in patients with AF include AF recurrence and selected stroke risk factors. The discontinuation of warfarin in a large number of patients with AF over time is a cause for concern in light of data from recent clinical trials.

AB - Warfarin is underused for stroke prevention in atrial fibrillation (AF). Previous studies addressing this have lacked longitudinal assessment. This study sought to characterize contemporary warfarin use in new-onset AF and evaluate its change over time. It was hypothesized that AF recurrence has an important influence on warfarin use patterns. One thousand five adults from 17 centers in the United States and Canada were enrolled into a prospective observational registry after their first documented episodes of AF. Detailed demographic, clinical history, and management data were collected on all subjects at enrollment, including medication use. Patients were followed at regular intervals for interim events and changes in AF management. Warfarin use at baseline and last follow-up (mean 25 ± 8 months) after enrollment was modeled using multivariate analysis. Initially, 65% of subjects were prescribed warfarin, but only 44% were taking it at 30 months. Even in "ideal" candidates for warfarin, the rate of warfarin prescription decreased from 70% at baseline to 50% at 30 months. Stroke risk factors, including hypertension, congestive heart failure, valvular heart disease, and previous stroke or transient ischemic attack were significant predictors of warfarin prescription at baseline. At last follow-up, the relation between AF recurrence and warfarin use (odds ratio 2.3, 95% confidence interval 1.6 to 3.1) was stronger than that for any individual stroke risk factor. In conclusion, predictors of warfarin use in patients with AF include AF recurrence and selected stroke risk factors. The discontinuation of warfarin in a large number of patients with AF over time is a cause for concern in light of data from recent clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=31944446445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31944446445&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2005.09.086

DO - 10.1016/j.amjcard.2005.09.086

M3 - Article

C2 - 16461052

AN - SCOPUS:31944446445

VL - 97

SP - 538

EP - 543

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 4

ER -